We are delighted to have Carrie Cox join the Candel team and lead our Board of Directors. Her strategic insights will be key as we advance our late stage pipeline of agents with the potential to become important medicines for patients with cancer.
Prof Paul Peter Tak is my guest on the podcast this week. He talks to me about growing up in the Netherlands. his medical career and how he ended up specializing in Rheumatology. We chat about his impressive career in Rheumatology research, his massive contributions to the field and how he wants to make a real impact on patients lives.
Listen to the podcast: https://unravellingscience.podbean.com/e/episode-23-prof-paul-peter-tak-rheumatology-big-impact-and-comfort-zones/
James is joined by Dr. Paul-Peter Tak, Venture Partner at Flagship Pioneering and CEO of Kintai Therapeutics. Over a more than 25-year career in the life sciences, Paul-Peter has created and led multiple companies. From 2011 until 2017, Paul-Peter founded and served as senior vice president and head of the immuno-inflammation therapy area unit at GSK. Under Paul-Peter’s leadership, this unit brought more than 10 new mechanisms of action into the clinic. From 2016 until 2018, Paul-Peter was senior vice president of R&D pipeline, chief immunology officer, development leader, and co-chair of GSK’s scientific review board. He oversaw the creation of a new portfolio of medicines in oncology, with a focus on immuno-oncology, epigenetics, and cell and gene therapy.
listen to the podcast: https://podcasts.apple.com/us/podcast/episode-35-story-flagship-pioneering-future-medicines/id1438968893?i=1000446446139
Careers in Discovery is your window into the world of Pharma & Biotech. Featuring interviews each week with leaders in Drug Discovery and R&D, you’ll learn about the careers of these influential figures, the work they are doing, how they got to where they are and what advice they’d give their younger selves. Brought to you by Singular Talent (http://www.singulartalent.io).
Listen to the podcast: https://anchor.fm/careers-in-discovery/episodes/Paul-Peter-Tak-ellm5q
In this episode, Paul-Peter Tak joins Monica Westley to discuss his innovative ideas within the type 1 diabetes space and how immunology can play a role in helping find a cure for T1D. Paul-Peter is an immunologist, academic, and venture partner who has specialized in the fields of rheumatology and immunology.
Paul-Peter Tak- “I think the future is clearly in looking at type 1 diabetes in a different way. I would almost reclassify it (as an immunologist, not necessarily as a diabetes expert) and I would call it pancreatic autoimmunity.”
Listen to the podcast: https://www.listennotes.com/podcasts/thesugarscience/episode-10-paul-peter-tak-XMmxuQl-5Cv/
In biotech, DR. PAUL-PETER TAK, the CEO of Kintai Therapeutics gives us a bigger picture of our gut – it’s not just your microbiome that plays a significant role in the recovery from illness.
Listen to the podcast: https://www.podomatic.com/podcasts/technation/episodes/2020-08-25T13_47_53-07_00
Cambridge, UK and Montreal, Canada – 5 May, 2021 – BIOS Health, a pioneer in the development of neural interfaces, has appointed world-renowned immunologist and biotechnology business leader, Paul Peter Tak, MD PhD, as an advisor.
View article: https://www.bios.health/bios-appoints-paul-peter-tak
Backed by GlaxoSmithKline and Boston’s SV Health Investors, a new biopharmaceutical company known as Sitryx launched with $30 million in a Series A funding round to develop disease-modifying therapeutics in immuno-oncology and immuno-inflammation.
View article: https://www.biospace.com/article/u-k-based-startup-sitryx-backed-by-gsk-as-to-target-immunometabolic-targets/
The vast majority of immune cells are found in the gut but historically, the gut has been viewed as a liability to drug development. The question of whether or not greater understanding of harnessing the gut could drive more promising drug development has led to the formation of a new company, Kintai Therapeutics.
View article: https://www.biospace.com/article/exclusive-flagship-ventures-company-kintai-therapeutics-focuses-on-enteric-therapeutics/
© Paul Peter Tak.
All rights reserved.